Home World News FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of... World News FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer By Ogkologos - March 23, 2026 586 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FX-909-CLINPRO-1 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Two Drugs Work Together to Block ‘Master Regulator’ of Breast, Other... September 4, 2018 FDA Approves Pembrolizumab Combination for the First-Line Treatment of Cervical Cancer October 15, 2021 Similar Disease-Free Survival with Extended Intermittent or Continuous Treatment with Letrozole... August 11, 2021 Grabbing the Perfect Gift December 16, 2023 Load more HOT NEWS Boy Battling Cancer Becomes Honorary Police Officer, Sworn In To 45... Molecular Profiling Identifies Targetable Alterations in Majority of Patients with Advanced... Contraception and cancer – a look behind the headlines Woman Diagnosed with Breast Cancer at 33 Launches Self-Examination App
